Mecir L.P.

Tamsulosin Hydrochloride, the active ingredient in Mecir L.P., is a alpha‑1 adrenergic antagonist presented as an oral tablet for oral use. It treats benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms in adult men.

GNH USA supplies Mecir L.P. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mecir L.P. (tamsulosin) is used in the management of conditions affecting the prostate and urinary outflow. - Benign prostatic hyperplasia: improves urinary flow and reduces bladder outlet obstruction. - Lower urinary tract symptoms associated with BPH: lessens urgency, frequency and nocturia. - Acute urinary retention due to BPH: facilitates bladder emptying and reduces the need for catheterisation.

Tamsulosin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Headache. - Nasal congestion or runny nose. - Abnormal ejaculation, including reduced volume or retrograde flow. - Orthostatic hypotension.

Serious or Rare Side Effects: - Priapism (prolonged painful erection). - Severe hypotension leading to fainting. - Allergic reactions such as rash, itching or swelling. - Angioedema involving face, lips or throat.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: watch for orthostatic drops, especially after the first dose. - Hepatic function: use caution in patients with moderate to severe liver impairment. - Concomitant alpha‑blockers: avoid additive hypotensive effects. - Renal function: assess in patients with severe renal insufficiency. - History of priapism: discontinue if this occurs. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Tamsulosin can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase tamsulosin levels. - Other alpha‑1 blockers (e.g., prazosin, doxazosin): risk of additive hypotension. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Antihypertensives and diuretics: monitor blood pressure for excessive lowering. - NSAIDs: may increase risk of renal impairment. - Warfarin: observe INR as tamsulosin can occasionally affect anticoagulation.